Pfizer’s Penbraya vaccine receives USFDA approval for most common serogroups causing meningococcal disease in adolescents

Penbraya(meningococcal groups A, B, C, W, and Y vaccine), the first and only pentavalent vaccine reduces the total number of doses needed for individuals to be fully vaccinated against the five most common serogroups, thereby streamlining the standard of care and potentially increasing the number of adolescents and young adults vaccinated, a statement said.